SOLARA705.85

Solara Active Pharma Sciences Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹3,142 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,288.91,283.81,369.01,431.4
Other Income5.48.36.27.9
Total Income1,294.31,292.11,375.11,439.3
Expenses
+ Cost of Materials Consumed760.7581.7672.8688.4
+ Purchases of Stock-in-Trade5.15.83.54.4
+ Changes in Inventories39.339.08.341.7
+ Employee Benefit Expense243.9211.7219.2221.6
+ Finance Costs105.1114.894.892.5
+ Depreciation & Amortisation103.399.399.7102.8
+ Other Expenses335.2239.4278.5283.7
Total Expenses1,592.51,291.51,376.71,435.0
EBITDA-95.2206.3186.8191.7
EBIT-198.5107.087.188.9
Profit
PBT before Exceptional Items-298.30.5-1.54.3
+ Exceptional Items-190.20.0-5.9-5.9
Pretax Income-488.40.5-7.4-1.6
+ Deferred Tax78.50.00.00.0
Tax Expense78.50.00.00.0
Net Income-567.00.5-7.4-1.6
+ Net Income — Continuing Ops-567.00.5-7.4-1.6
+ Other Comprehensive Income0.51.02.92.8
Total Comprehensive Income-566.51.5-4.61.2
Net Income to Common-567.40.5-7.4-1.6
Minority Interest0.4-0.00.00.0
Per Share
Basic EPS-157.620.14-1.68-0.62
Diluted EPS-157.620.14-1.68-0.62
Other Comprehensive Income — detail
+ Other Comprehensive Income1.02.92.8
+ Items NOT to be Reclassified to P&L0.61.13.3
+ Items to be Reclassified to P&L-0.1-0.1-0.4-0.5
Comprehensive Income — Owners of Parent-566.91.02.9-14.6
Comprehensive Income — Non-controlling Interests0.40.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-157.620.14-1.68-0.62
Diluted EPS — Continuing Operations-157.620.14-1.68-0.62
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit483.9657.4684.5697.0
Gross Margin %37.5451.2150.0048.69
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-298.30.5-1.54.3
− Exceptional Items (reconciliation)-190.20.0-5.9-5.9
Net Income Adj (tax-effected)-376.80.5-1.54.3
EPS Adj-104.750.14-0.341.63
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital36.040.344.548.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.